Takeda Pharmaceutical Co. Ltd. is restructuring by consolidating site operations and integrating legacy Nycomed operations. The company will align Nycomed’s former operation structures and processes with the Takeda global headquarters in Japan and the newly defined organizations of the chief commercial officer, headquartered in Zurich, Switzerland, and chief medical and scientific officer, headquartered in Deerfield, IL, and its expanded affiliate network worldwide.

Takeda will consolidate its R&D sites and functions, cutting its global workforce by approximately 2,800 (2,100 in Europe and 700 in the U.S.) by the end of fiscal 2015 across the functions of R&D, commercial, operations and G&A, the cost of which is estimated at approximately 70 billion Yen during fiscal 2011 – 2015. During this period, the company expects to save approximately 200 billion Yen.

“The combination of Takeda and Nycomed, which we acquired on September 30, 2011, brought together Takeda’s strong presence in the Japanese and U.S. markets with the legacy Nycomed business infrastructure in Europe and high-growth emerging markets,” said Yasuchika Hasegawa, president and chief executive officer, Takeda Pharmaceutical Co. “While our combined operations in more than 70 countries are more complementary than overlapping, there are a number of areas where we will need to make changes to ensure efficient and flexible operations moving forward.”

Takeda’s plan includes shifting from a product portfolio centered on mature, high selling products to a more diverse portfolio focused on new products. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.